RnRMarketResearch.com adds “HIV-1 Infection – Pipeline Review, H2 2014” report to its research database. The report provides an overview of the HIV-1 Infection’s therapeutic pipeline.
Dallas, TX -- (SBWIRE) -- 11/06/2014 -- This report provides comprehensive information on the therapeutic development for HIV-1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV-1 Infection and special features on late-stage and discontinued projects.
HIV-1 is the most common and pathogenic strain of the virus. Scientists divide HIV-1 into a major group (Group M) and two or more minor groups. Each group is believed to represent an independent transmission of SIV into humans (but subtypes within a group are not). A total of 39 ORFs are found in all six possible reading frames (RFs) of HIV-1 complete genome sequence, but only few of them are functional.
Complete Report Available
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
HIV-1 Infection - Companies Involved in Therapeutics Development:
AbbVie Inc., AlphaVax, Inc., AltraVax Inc., Amunix, Inc., Aphios Corporation, Argos Therapeutics, Inc., Bionor Pharma ASA, Biosantech SA, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Critical Outcome Technologies Inc., CytoDyn Inc., Enzo Biochem, Inc., FIT Biotech Oyj, GeneCure LLC, Gilead Sciences, Inc., GlaxoSmithKline plc, InnaVirVax SA, Inovio Pharmaceuticals, Inc., Johnson & Johnson, Kaketsuken K.K., Koronis Pharma, Inc., Merck & Co., Inc., Mymetics Corporation, Myrexis, Inc., Oncovir, Inc., OyaGen Inc., Peregrine Pharmaceuticals, Inc., Pfizer Inc., Pharis Biotec GmbH, RFS Pharma, LLC, Spider Biotech, TaiMed Biologics Inc., Takara Bio Inc., THERAVECTYS SA, Tobira Therapeutics, Inc., United Biomedical, Inc., Valens Therapeutics, Inc., Vichem Chemie Research Ltd., ViiV Healthcare.
Order a Purchase copy
-The report provides a snapshot of the global therapeutic landscape of HIV-1 Infection
-The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved in the therapeutics development for HIV-1 Infection and enlists all their major and minor projects
-The report summarizes all the dormant and discontinued pipeline projects
-A review of the HIV-1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-A detailed assessment of monotherapy and combination therapy pipeline projects
-Coverage of the HIV-1 Infection pipeline on the basis of target, MoA, route of administration and molecule type
-Latest news and deals relating related to pipeline products
Reasons to buy:
-Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Develop strategic initiatives by understanding the focus areas of leading companies
-Identify and understand important and diverse types of therapeutics under development for HIV-1 Infection
-Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
-Devise corrective measures for pipeline projects by understanding HIV-1 Infection pipeline depth and focus of Indication therapeutics
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Browse more reports on Infectious Diseases Therapeutics Market